Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia
Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  • Phase

    Phase 1
  • Study Type

  • Status

  • Intervention/Treatment

    ucart123 ...
  • Study Participants

Phase I, first-in-human, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Study Started
Jun 19
Primary Completion
Mar 31
Study Completion
Mar 31
Last Update
Jun 07

Biological UCART123v1.2

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor

Part 1: Dose Escalation Experimental

Several tested doses of UCART123v1.2 with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D) Dose Expansion: UCART123v1.2 administered at the selected dose determined from the dose escalation phase


Main Inclusion Criteria:

Patients with relapsed or primary refractory AML (as defined in WHO criteria) with >5% bone marrow blasts
Patients with CD123+ blast cells (verified by flow cytometry)
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1
Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
(Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
Other criteria may apply

Main Exclusion Criteria:

Patients with APL or CNS Leukemia
Previous investigation gene or cell therapy (including CAR)
≥ 2 prior allogeneic SCTs
Prior treatment with rituximab or other anti-CD20 therapy within 3 months
Any known active or uncontrolled infection
Other criteria may apply
No Results Posted